fc 1

3-CPMT (FC-1) is a dopamine uptake inhibitor and a potent long-acting antihistaminic agent.

Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO cells, targeting Fc gamma R1. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

FC 11 is a highly potent focal adhesion Ki nase (FAK) PROTAC®Degrader (DC50 values are 40 to 370 pM depending on cell line), which is composed of the FAK inhibitor PF 562217 joined by a linker to the cereblon-binding ligand Pomalidomide. The effects of FC 11 are reversible upon compound wash out. FC 11 also degrades autophosphorylated FAK (pFAKtyr397), displaying near complete degradation after 3 hours at 100 nM in TM3 cells.

Fc 11a-2, a benzimidazole compound, functions as an orally active, potent inhibitor of the NLRP3 inflammasome by blocking caspase-1 activation and thus preventing the activation of IL-1β/IL-18. Additionally, Fc 11a-2 inhibits the progression of Dextran sulfate sodium (DSS)-induced murine experimental colitis [1] [2] [3].

Fusarochromanone (FC-101) is a mycotoxin produced by Fusarium marcescens with potent antiangiogenic, anticancer and antimalarial activities. Fusarochromanone induces cell death in COS7 and HEK293 cells through activation of the JNK pathway.

BFC1108 targets Bcl-2 and converts it to a pro-apoptotic protein, inhibits the growth of triple-negative breast cancer xenografts with high Bcl-2 expression, inhibits breast cancer lung metastasis, and induces apoptosis of Bcl-2-expressing cancer cells.

Toremifene citrate is a selective estrogen receptor modulator (SERM). It is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on the mammary and uterine tissue.

PAF C-18 is a naturally occurring phospholipid molecule belonging to the platelet-activating factor (PAF) family, which acts as an intercellular signaling molecule involved in platelet aggregation, vasodilatation, and inflammatory responses.PAF C-18 is involved in hemostasis and thrombosis by binding to its specific G-protein-coupled receptor (PAFR) and activating.

FC-116 is a potent Tubulin inhibitor with antitumour activity and inhibits tumour growth in mice. FC-116 induces apoptosis in colorectal cancer (CRC) cells and promotes protein degradation.

FC-14367 is a PROTAC degrader targeting the HIV-1Nef protein. It forms a ternary complex by binding Nef with CereblonE3 ubiquitin ligase, inducing ubiquitination of Nef and its subsequent proteasomal degradation. This restores cell surface CD4 and MHC-I expression, inhibiting HIV-1 replication. FC-14367 is useful for research on HIV infection and AIDS.

FC-14369 is a PROTAC degrader targeting the HIV-1Nef protein (HIV-1Nef protein) with a DC50 value of 160 nM. By means of its bifunctional structure, FC-14369 binds to both Nef and Cereblon E3 ubiquitin ligase, facilitating Nef ubiquitination and proteasomal degradation. This action restores the expression of cell surface CD4 and MHC-I, thereby inhibiting HIV-1 replication. FC-14369 is applicable in the study of HIV infection and AIDS.

Toremifene (GTx 006) is a selective estrogen-receptor modulator (SERM).

AZ82 is a selective inhibitor of kinesin-like protein KIFC1 (HSET/KIFC1), with a Ki of 43 nM and an IC50 of 300 nM for KIFC1.

CXCR4 antagonist

SR31527 (SR31527 chloride) is a potent KIFC1 inhibitor with an IC50 of 6.6 µM against KIFC1. SR31527 chloride has a moderate inhibitory effect on cell viability and colony formation.

Lyso-PAF C-16 is a substrate for PAF C-16, also obtainable via enzymatic acylation of arachidonic acid, suitable for biochemical experiments.

KP1019 is now discontinued.

Methylcarbamyl PAF C-16 (Carbamyl-PAF) is a platelet-activating factor analogue with PAF agonist properties, activating inflammation in pregnancy tissues and promoting preterm birth.

PAF C-18:1 is a naturally occurring phospholipid produced by cells upon stimulation and plays a role in the establishment and maintenance of the inflammatory response. It is less potent than PAF C-16 and PAF C-18 in the induction of neutrophil chemotaxis, but is equipotent to PAF C-16 and PAF C-18 in promoting eosinophil migration. PAF C-18:1 activates the PAF receptor and has been used in antibody binding experiments to determine the importance of an acyl linkage at the sn-2 position for recognition at this receptor.

PAF C-16 is a naturally occurring phospholipid produced upon stimulation through two distinct pathways known as the remodeling" and 'de novo' pathways. It is a potent mediator of neutrophil migration and the production of reactive oxygen species and IL-6. Pathological processes involving PAF include necrotizing enterocolitis

Pralatrexate (10-Propargyl-10-deazaaminopterin) is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities.

Ospemifene (FC-1271a) is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.

Argtide is an luteinizing hormone releasing hormone (LHRH) antagonist.

FC11409B is a CAIX inhibitor, inhibiting breast cancer invasion and metastasis.